ALDVI logo

Advicenne S.A. Stock Price

ENXTPA:ALDVI Community·€23.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

ALDVI Share Price Performance

€1.63
-0.48 (-22.56%)
€1.63
-0.48 (-22.56%)
Price €1.63

ALDVI Community Narratives

There are no narratives available yet.

Snowflake Analysis

Moderate risk and fair value.

5 Risks
2 Rewards

Advicenne S.A. Key Details

€5.9m

Revenue

€6.9m

Cost of Revenue

-€962.0k

Gross Profit

€8.7m

Other Expenses

-€9.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.68
-16.32%
-164.45%
-77.8%
View Full Analysis

About ALDVI

Founded
2007
Employees
13
CEO
Didier Laurens
WebsiteView website
www.advicenne.com

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.

Recent ALDVI News & Updates

Recent updates

No updates